Pure Global
NCT05744401

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants With Alzheimer's Disease
Alector Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
AL002
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Alector Inc.
Location
Hattiesburg,Neptune,Portland, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jan 04, 2023
End date
Dec 01, 2025
Enrollment
190 participants
Primary outcome

Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs.,Safety and tolerability as measured by the number of MRI abnormalities.,Effect of Immunogenicity as measured by ADAs titers.

Summary

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in
 participants with Early Alzheimer's Disease.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05744401
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05744401 through Pure Global AI's free database. This Phase 2 trial is sponsored by Alector Inc. and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 190 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.